Hi all,
I'm at NBCCF's advocacy conference in Washington DC. Anyone else on this list here too? It would be nice to say hello.
I picked up a flyer for Genentech/Roche's Phase III "Emilia" T-DM1 trial. T-DM1 vs. capecitabine (xeloda) and lapatinib (tykerb). I don't see it listed on this forum, so thought I'd post it.
Inclusion: HER2+, prior tx with both a taxane (alone or in combo with another agent), and Herceptin, documented progression of locally advanced or mets bc, LVEF >50%, ECOG 0-1.
Exclusion: Long list - the biggest ones to me look to be prior lapatinib or capecitabine, existing neuropathy grade 3 or greater.
Now enrolling - more info:
www.clinicaltrials.gov or call the Genentech Trial Information Support Line at 888-662-6728.
Debbie Laxague
Threaded Mode